Johnson & Johnson’s stock rose 1.9% early Wednesday, after the medical tech and drug company posted better-than-expected earnings for the fourth quarter, offsetting mixed guidance. The company had per ...
Johnson & Johnson (NYSE: JNJ) is proud to announce a Canadian first: the publication of a consensus statement titled, "Optimizing the management of psoriasis in patients with skin of colour: a ...
Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...
Some results have been hidden because they may be inaccessible to you